Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
- 1 July 1995
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 109 (1) , 129-135
- https://doi.org/10.1016/0016-5085(95)90277-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Low-Dose Cyclosporine for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993
- Soluble receptors for tumour necrosis factorAIDS, 1993
- CD4 Antibody Treatment in Crohn's DiseaseScandinavian Journal of Gastroenterology, 1992
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's DiseaseNew England Journal of Medicine, 1989